Patient Portal

Richard Leo Wahl, MD

Elizabeth Mallinckrodt Professor, Radiology
Chairman, Department of Radiology
Director, Mallinckrodt Institute of Radiology

Specialty Areas

Diagnostic Radiology
Nuclear Medicine
Nuclear Radiology

Board Certifications

Nuclear Medicine
Diagnostic Radiology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

PET/CT imaging, radiopharmaceutical therapies, nuclear Imaging

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Mallinckrodt Institute of Radiology

510 South Kingshighway Boulevard
St. Louis, MO 63110

Office Phone: (314) 362-7100

Education

Education

Medical Degree: Washington University School of Medicine, St. Louis, MO 1978
ScD: Wartburg College, Waverly, IA 2008
Fellowship, Nuclear Medicine: Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 1983
Fellowship (research), Immunology: Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 1983
BA, Chemistry: Wartburg College, Waverly, IA 1974
Residency, Diagnostic Radiology: Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 1982

Publication & Research

Publication & Research

SNMMI Leadership Update: New Initiatives in Research and Discovery.
Wahl RL
J Nucl Med. 2018 Dec; 59(12)22N.

PMID:
    30510078
    [PubMed - in process]
Related citations


Dynamic whole-body PET imaging: principles, potentials and applications.
Rahmim A, Lodge MA, Karakatsanis NA, Panin VY, Zhou Y, McMillan A, Cho S, Zaidi H, Casey ME, Wahl RL
Eur J Nucl Med Mol Imaging. 2018 Sep 29; doi: 10.1007/s00259-018-4153-6.

PMID:
    30269154
    [PubMed - as supplied by publisher]
Related citations


Reply: Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks
Duncan JR, Lieber MR, Adachi N, Wahl RL
J Nucl Med. 2018 Nov; 59(11)1780-1781. doi: 10.2967/jnumed.118.218321.

PMID:
    30262519
    [PubMed - in process]
Related citations


The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.
Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM
Int J Radiat Oncol Biol Phys. 2018 Nov 15; 102(4)1219-1235. doi: 10.1016/j.ijrobp.2018.06.023.

PMID:
    29966725
    [PubMed - in process]
Related citations


Spatial relationship of 2-deoxy-2-[<sup>18</sup>F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer.
Floberg JM, Fowler KJ, Fuser D, DeWees TA, Dehdashti F, Siegel BA, Wahl RL, Schwarz JK, Grigsby PW
EJNMMI Res. 2018 Jun 15; 8(1)52. doi: 10.1186/s13550-018-0403-7.

PMID:
    29904822
    [PubMed]
Related citations


Radiation Dose Does Matter: Mechanistic Insights into DNA Damage and Repair Support the Linear No-Threshold Model of Low-Dose Radiation Health Risks.
Duncan JR, Lieber MR, Adachi N, Wahl RL
J Nucl Med. 2018 Jul; 59(7)1014-1016. doi: 10.2967/jnumed.118.210252.

PMID:
    29853652
    [PubMed - in process]
Related citations


Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.
Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, Feiweier T, Kamel IR, Wahl RL, Pan L
Acad Radiol. 2018 Nov; 25(11)1405-1414. doi: 10.1016/j.acra.2018.02.010.

PMID:
    29627288
    [PubMed - in process]
Related citations


Measurement of Brown Adipose Tissue Activity Using Microwave Radiometry and <sup>18</sup>F-FDG PET/CT.
Crandall JP, O JH, Gajwani P, Leal JP, Mawhinney DD, Sterzer F, Wahl RL
J Nucl Med. 2018 Aug; 59(8)1243-1248. doi: 10.2967/jnumed.117.204339.

PMID:
    29439011
    [PubMed - in process]
Related citations


Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach.
Valenta I, Varga ZV, Valentine H, Cinar R, Horti A, Mathews WB, Dannals RF, Steele K, Kunos G, Wahl RL, Pomper MG, Wong DF, Pacher P, Schindler TH
JACC Cardiovasc Imaging. 2018 Feb; 11(2 Pt 2)320-332. doi: 10.1016/j.jcmg.2017.11.019.

PMID:
    29413441
    [PubMed - in process]
Related citations


PERCIST in Perspective.
O JH, Wahl RL
Nucl Med Mol Imaging. 2018 Feb; 52(1)1-4. doi: 10.1007/s13139-017-0507-4.

PMID:
    29391906
    [PubMed]
Related citations


Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with <sup>89</sup>Zr in Human Lymphoma Xenografts.
Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL
J Nucl Med. 2018 Aug; 59(8)1219-1224. doi: 10.2967/jnumed.117.203299.

PMID:
    29348316
    [PubMed - in process]
Related citations


Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms.
Mhlanga JC, Chirindel A, Lodge MA, Wahl RL, Subramaniam RM
Nucl Med Commun. 2018 Feb; 39(2)154-160. doi: 10.1097/MNM.0000000000000786.

PMID:
    29227348
    [PubMed - indexed for MEDLINE]
Related citations


Non-invasive methods for the assessment of brown adipose tissue in humans.
Chondronikola M, Beeman SC, Wahl RL
J Physiol. 2018 Feb 1; 596(3)363-378. doi: 10.1113/JP274255.

PMID:
    29119565
    [PubMed - in process]
Related citations


DNA Repair After Exposure to Ionizing Radiation Is Not Error-Free.
Duncan JR, Lieber MR, Adachi N, Wahl RL
J Nucl Med. 2018 Feb; 59(2)348. doi: 10.2967/jnumed.117.197673.

PMID:
    28775198
    [PubMed - in process]
Related citations


Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D
Neuro Oncol. 2017 Jun 1; 19(6)845-852. doi: 10.1093/neuonc/nox020.

PMID:
    28371832
    [PubMed - indexed for MEDLINE]
Related citations


Quantitation of Cancer Treatment Response by <sup>18</sup>F-FDG PET/CT: Multicenter Assessment of Measurement Variability.
O JH, Jacene H, Luber B, Wang H, Huynh MH, Leal JP, Wahl RL
J Nucl Med. 2017 Sep; 58(9)1429-1434. doi: 10.2967/jnumed.117.189605.

PMID:
    28360211
    [PubMed - indexed for MEDLINE]
Related citations


Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point <sup>18</sup>F-FDG PET/CT Imaging in Patients with Advanced Melanoma.
Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL
J Nucl Med. 2017 Sep; 58(9)1421-1428. doi: 10.2967/jnumed.116.188839.

PMID:
    28360208
    [PubMed - indexed for MEDLINE]
Related citations


The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.
Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA
J Neurooncol. 2017 May; 132(3)513-519. doi: 10.1007/s11060-017-2404-1.

PMID:
    28315063
    [PubMed - indexed for MEDLINE]
Related citations


Simplifying volumes-of-interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole-organ VOIs.
Vicente EM, Lodge MA, Rowe SP, Wahl RL, Frey EC
Med Phys. 2017 May; 44(5)1707-1717. doi: 10.1002/mp.12164.

PMID:
    28207950
    [PubMed - indexed for MEDLINE]
Related citations


A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.
Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL
EJNMMI Res. 2017 Dec; 7(1)8. doi: 10.1186/s13550-017-0258-3.

PMID:
    28102506
    [PubMed]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2017:

Company Name: Nihon Mediphysics

Royalties:

Equity: No

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2018


Company Name: Clarity

Royalties:

Equity: No

Consulting/Advisory Board: $10,000 - $19,999

Speaker Fees:

Reporting Date: May 01, 2018

Areas of Research Interest

Quantitative imaging, radioimmunotherapy, imaging the immune system, multi-modality imaging